Deep Knowledge Group
VC Fund
London, United Kingdom
Deep Knowledge Group is a data-driven consortium of commercial and non-profit organizations active on many fronts in the realm of DeepTech and Frontier Technologies (AI, Longevity, BioTech, Pharma, FinTech, GovTech, SpaceTech, FemTech, Data Science, InvestTech), ranging from scientific research to investment, entrepreneurship, analytics, consulting, media, philanthropy and more. As a mathematical corporation focused on building the bridge to the 5th Industrial Revolution, Deep Knowledge Group is decisively committed to DeepTech for Social Good, Techno-Philanthropy and DeepTech and Longevity Industry Financial Commoditization (establishing the core investment and financial industry infrastructure needed for the emergence of DeepTech and Longevity as fundamentally new asset classes). Deep Knowledge Group has been committed since 2014 to the corporate thesis of DeepTech for social impact, techno-ethical business for social good, and the continual reinvestment of profits into the expansion of our core Data Science, AI and analytics assets and the refinement of our financial-ecosystemic development projects (which we see as the major tool driving our Group’s further growth as a Data Science driven financial corporation with focus on Longevity and DeepTech). Our unique approach lies in combining ecosystemic financial innovations with sophisticated AI and Data Science technology development for DeepTech and Longevity Industry analysis, benchmarking and forecasting. We remain committed as always to developing and deploying reliably sophisticated and multidimensional Big Data analytics and AI driven technological forecasting and benchmarking of DeepTech, Longevity and related industries, pioneering the fundamental tools required for strategic decision making in these unprecedentedly complex and innovation-driven sectors, laying the foundation and basis for defining, thinking about and understanding the coming DeepTech Revolution. However, more than this, the Group remains just as decisively committed to the practical execution of many of these forecasted developments by establishing the core investment and financial industry infrastructure (platforms, indices, exchanges, financial instruments and derivatives) needed for accelerated and de-risked DeepTech and Longevity Industrialization, and their emergence as fundamentally new asset classes.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 38%
- Fund size:
- $100M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Deep Knowledge Group invests in
Stages Deep Knowledge Group invests in
Countries Deep Knowledge Group invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 8 contacts → | |||
Investment Focus
Industry
- Health Care 6 (46%)
- Biotechnology 6 (46%)
- Market Research 3 (23%)
- Medical 2 (15%)
- Analytics 2 (15%)
Stage
- Seed 11 (85%)
- Convertible Note 1 (8%)
Country
- United Kingdom 5 (38%)
- United States 3 (23%)
- Hong Kong 2 (15%)
- Canada 1 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alexei Cresniov
Director of Deep Knowledge Analytics and GovTech Analytics
|
Director of Deep Knowledge Analytics and GovTech Analytics | Total investments: 0 | Find email | |
Andrey Teterin
Leading Data Scientist
|
Leading Data Scientist | Total investments: 0 | Find email | |
Dmitry Kaminskiy
General Partner and Founder
|
General Partner and Founder | Total investments: 0 | Find email | |
Dmitry Matchihine
Visionary Partner, Blockchain Geek
|
Visionary Partner, Blockchain Geek | Total investments: 0 | Find email | |
Franco Cortese
Partner
|
Partner | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| ongevity and DeepTech Financial Advisors Ltd. is a leading advisory boutique focused on the Longevity and DeepTech industries. Its shareholders and senior managers have built up significant expertise in private and public capital markets, as well as a substantial network of companies operating in the industry. They provide intermediary financialservices that are deployed in the form of an interactive online semi-automated IT-platform designed for end-users of investment products and services. They serve as the WealthTech/InvestTech financial marketplace for professional investors, family offices, and institutional investors and provide industry-specific analytical systems to enable the significant optimisation of dealflow, stock selection, and execution capabilities for investors.The company is decisively committed to establishing the core investment and financial industry infrastructure (platforms, indices, exchanges, financial instruments and derivatives) needed to execute the concept of DeepTech and Longevity Financial Commoditization, reflected in its pursuit of a truly ecosystemic approach through its various financial service divisions to establish an integral financial infrastructure to support the commoditization of the DeepTech and Longevity Industries as fundamentally new asset classes. | Seed / Jan 08, 2022 | ||
| Deep Pharma Intelligence is a leading UK-based market intelligence agency focused on the emerging markets in the Pharmaceutical, Biotech, and Healthcare industries.Deep Pharma Intelligence, an analytical subsidiary of Deep Knowledge Group, is a highly specialised think tank in the area of biotech innovation profiling, market intelligence, andbiotech development advisory. The company is dedicated to producing powerful data mining and visualisation systems, interactive analytics tools, and industry reports offering deep technical insights, market intelligence, and strategic guidance in the high growth and significant opportunity areas.DPI specialisation - Artificial Intelligence in drug discovery, AI in oncology, cancer vaccines, emerging therapeutic targets and drug modalities, new therapies and technologies, promising startups, and more.Also, DPI provides strategic consulting, business development, and market intelligence services to top-tier Pharma corporations. Comprehensive competitive analysis based on innovation potential and business activity. | Seed / Mar 03, 2021 | ||
| We are making mobile banking experience easier and safer for people of all ages by developing new financial products in combination with cutting edge HealthTech and AgeTech designed for users who are planning to live extra long lives and want to remain high functioning and financially stable throughout. | Seed / May 06, 2020 | ||
| Aging Analytics Agency, analytical subsidiary of Deep Knowledge Group, is the world’s premier provider of industry analytics on the topics of Longevity, Precision Preventive Medicine and Economics of Aging, and the convergence of technologies such as AI, Blockchain, Digital Health and their impact on the healthcare industry. Services of the AgingAnalytics Agency: Longevity Market Intelligence and Industry Analytics, Validated Proprietary Analytics, Financial Analytics and Consulting on Government Longevity Policies.Longevity Market Intelligence and Industry Analytics covers emerging technologies, innovations, companies, and trends across the Longevity Industry.Validated Proprietary Analytics provides comprehensive due diligence, industry profiling, growth strategy development and technology analysisFinancial Analytics produce knowledge-based financial insights covering major developments in Longevity IndustryConsulting on Government Longevity Policies provides quantitative and qualitative insights that can be used to strengthen national healthcare systems. | Seed / Feb 18, 2020 | ||
| Deep Knowledge Analytics, an analytical subsidiary of Deep Knowledge Group, is a DeepTech-focused data provider producing advanced analytics on DeepTech and frontier-technology industries using sophisticated multi-dimensional frameworks and algorithmic methods to deliver insightful market intelligence, pragmatic forecasting and tangible industrybenchmarking.Deep Knowledge Analytics regularly produces open-access reports covering emerging technologies, innovations, companies, investors, governmental agencies activities and major trends across the DeepTech Industry in the UK. In 2020, a report on Covid-19, produced by Deep Knowledge Analytics, was providing data that governments such as United Kingdom and Israel were relying on for pandemic monitoring and decision making.Deep Knowledge Analytics has evolved from producing static analytical reports into interactive reports, which are a part of a Big Data Analytical System that consist of specialised Dashboards focused on DeepTech. This customised IT platform aims to improve decision-making process regarding technological innovations from both analytics and execution perspectives. It can serve as a one-stop automated data diagnostics and analytics platform for companies, start-ups, governmental bodies, and investors. | Seed / Jul 05, 2019 | ||
| DeepWave is the Leading Innovator in Using Neuroscience to Improve Sleep as the Gateway to Enhanced Cognitive Functioning and Health. | Seed / Sep 29, 2017 | ||
| Pathway Pharmaceuticals combined contemporary techniques in genetics, systems biology, bioinformatics and molecular biology and created an original ground breaking technology to discover the most effective available treatment plan that pertains to each patient’s particular case. It is the sole company currently undertaking such exclusive molecularanalysis of patients’ tissue samples consisting of profiling complete transcriptome, analyzing affected intracellular molecular signaling pathways and finding the best target therapeutics that may efficiently stop cancer progression in each case of individual patient’s tumor. Furthermore, Pathway Pharmaceuticals remains the only company that offers a complete analysis of clinical trials databases focused on the case of the individual patient, which sufficiently increases the success of therapy.The knowledge and skills of Pathway Pharmaceuticals board-certified medical review committee is the driving force of the whole diagnostic method. With the most modern technology, Pathway Pharmaceuticals can incorporate each patient’s tumor molecular assessment with his actual past medical history, to develop specific treatment strategy for each patient. The company engages top professionals in the field to constantly update and enhance its technological basis.In conclusion, Pathway Pharmaceuticals customized report in a creative manner merges together the medical history and the results of the molecular profiling, which leads to recommendation of certain target anticancer drugs. The procedure is fully user-friendly and offers multiple options which allow identification of the most effective treatment plan for each cancer patient individually. | Seed / Aug 25, 2015 | ||
| Canada Cancer and Aging Research Laboratories (CCARL) is a research and development company offering a personalized approach to cancer treatment. Empowered by decades of knowledge on molecular signatures of various cancers, sex- and age-specificity of cancer response to treatment, molecular and biochemical characteristics of regulation of variouspro- and anti-cancer pathways, CCARL has been able to generate a product that allows doctors to make case-by-case decisions as far as a patient’s treatment is concerned.CCARL combines the knowledge of genetics, epigenetics, the molecular and cellular biology of cancer with the information from all available public databases and their own profiling experiments to create a powerful tool that allows to develop the most effective and individualized cancer treatment plan.In Canada, CCARL has an exclusive license to use the power of OncoFinder, a unique integrated bioinformatic system developed by Pathway Pharmaceuticals (HongKong), for bringing personalized cancer treatment approaches to Canadians.CCARL is the sole research and development company in Canada that undertakes such an exclusive molecular analysis of patients’ tissue samples including complete transcriptome profiling, analyzing the affected intracellular molecular signaling pathways, and predicting the best target therapeutics that may efficiently stop cancer progression in each case of an individual patient’s tumor. Furthermore, CCARL remains the only company in Canada that offers a complete analysis of clinical trial databases focused on the case of each individual patient, which may sufficiently increase the success of therapy.The knowledge and skills of Pathway Pharmaceuticals and CCARL board-certified medical review committee is the driving force of the whole diagnostic method. CCARL is using the most modern technology to incorporate the molecular assessment of each patient’s tumor with his/her actual past medical history and propose a specific treatment strategy for each patient. Both companies engage top professionals in the field to constantly update and enhance the technological basis for the decision-making process.In conclusion, Canada Cancer and Aging Research Laboratory merges together a patient’s medical history with the results of molecular profiling of tumor samples, which leads to the recommendation of specifically targeted anticancer drugs. The procedure is fully user-friendly and offers multiple options that allow the identification of the most effective treatment plan for each cancer patient individually. | Seed / Jul 23, 2015 | ||
| Vision genomics, LLC is a biotechnology-based company that focuses on research and development of therapeutics for age-related eye diseases. Their company undertakes an interdisciplinary approach using big data analysis to produce working solutions for age-related eye diseases.Their primary disease of interest is Age-related maculardegeneration (AMD). AMD is the leading cause of visual impairment and blindness in older adults and one of the most common causes of visual impairment worldwide. Vision Genomics, LLC is focused on operations and development of its AMD Medicine TM drug discovery with a personalized medicine platform. AMD Medicine TM was developed using the advanced genomic and transcriptomic analysis algorithms already successfully used in cancer research and precision medicine in oncology.The AMD Medicine platform contains broad databases of gene expression, genetic and epigenetic data in ocular diseases as databases of drugs with known molecular targets and effects on gene expression in a variety of tissues and cell lines. It includes advanced parametric and machine learning algorithms that screen for drugs that minimize the difference between healthy and disease states while targeting signaling pathways that are pathologically activated or down regulated and accounting for pharmacogenomic effects.For years the founding scientists have engaged in projects related to the understanding of the interplay of inter-cellular signaling pathways in age-related diseases and progeroid syndromes and have looked for interventions to modulate and delay the onset of the pathological processes resulting from and driving aging.Age-related macular degeneration (AMD) was identified as one of the disease models , in which some of the interventions may be effective. To accelerate research scientists decided to form a company and engage with the country’s top ophthalmologists to find working personalized solutions for AMD. | Seed / Apr 15, 2015 | ||
| Atlas Regeneration is developing pioneering bioinformatics solutions for regenerative medicine. The company is based in Winston-Salem. | Seed / Jan 10, 2015 | ||
| See all 13 investments → | |||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Deep Knowledge Group invest in?
Deep Knowledge Group invests primarily in Health Care, Biotechnology and Market Research startups, most often at Seed and Convertible Note stage. Most of the 13 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Deep Knowledge Group?
Public channels for Deep Knowledge Group include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Deep Knowledge Group?
The team at Deep Knowledge Group includes Alexei Cresniov (Director of Deep Knowledge Analytics and GovTech Analytics), Andrey Teterin (Leading Data Scientist) and Dmitry Kaminskiy (General Partner and Founder), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
